241 related articles for article (PubMed ID: 31821071)
21. Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.
Nakamura T; Toshimoto K; Lee W; Imamura CK; Tanigawara Y; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Jul; 7(7):474-482. PubMed ID: 29920987
[TBL] [Abstract][Full Text] [Related]
22. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Lee CI; Low SK; Maldonado R; Fox P; Balakrishnar B; Coulter S; de Bruijn P; Koolen SLW; Gao B; Lynch J; Zdenkowski N; Hui R; Liddle C; Mathijssen RHJ; Wilcken N; Wong M; Gurney H
Breast; 2020 Dec; 54():229-234. PubMed ID: 33161337
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Marcath LA; Deal AM; Van Wieren E; Danko W; Walko CM; Ibrahim JG; Weck KE; Jones DR; Desta Z; McLeod HL; Carey LA; Irvin WJ; Hertz DL
Pharmacogenet Genomics; 2017 Nov; 27(11):402-409. PubMed ID: 28877533
[TBL] [Abstract][Full Text] [Related]
24. Individualization of tamoxifen treatment for breast carcinoma.
Binkhorst L; van Gelder T; Mathijssen RH
Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
[TBL] [Abstract][Full Text] [Related]
25. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
[TBL] [Abstract][Full Text] [Related]
26. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
[TBL] [Abstract][Full Text] [Related]
29. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
[TBL] [Abstract][Full Text] [Related]
30. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
31. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
32. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
[TBL] [Abstract][Full Text] [Related]
35. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
36. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
[No Abstract] [Full Text] [Related]
38. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
de Vries Schultink AHM; Huitema ADR; Beijnen JH
Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
[TBL] [Abstract][Full Text] [Related]
40. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]